You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: Kaps Biotechnology LLC            Topic: 102

    Abstract Prostate cancer (CaP) is the most common non-skin cancer in men and third most common cause of cancer deaths in men. Black men experience a higher burden of incidence and mortality from CaP compared to White men. The Prostate-Specific Antigen (PSA) test, a commonly used biomarker for early diagnosis and management of CaP, cannot alone accurately predict the presence of CaP, its aggressive ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARY Multiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. There is no cure for the disease and current treatments focus on preventing future immunological attacks, mainly by suppressing the ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. A small molecule integrin activator to enhance cord blood transplant

    SBC: 7 Hills Pharma LLC            Topic: NHLBI

    PROJECT SUMMARY This proposal is in response to the parent announcement for Phase II STTR (R42) grant applications. Hematopoietic stem cell transplantation has become a preferred treatment for hematological malignancies and certain genetic disorders. Umbilical cord blood has become an appealing alternative to bone marrow or peripheral blood as a source of hematopoietic stem cells for transplant. D ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Non-invasive Detection of Cerebral Aneurysm Recurrence after Endovascular Treatment Using Automated Image Processing

    SBC: Medical Innovators Company, LLC            Topic: 101

    PROJECT SUMMARY Hemorrhage due to cerebral aneurysm rupture is a devastating condition with high mortality. For the more than 30,000 patients in the US who are diagnosed annually with an aneurysm, treatment consists of preventing rupture, and increasingly relies of endovascular techniques. However, treatment durability is unknown with recurrence estimated at 16-40% and the re-treatment of 10-20%. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement

    SBC: POLYNOVA CARDIOVASCULAR INC            Topic: NHLBI

    Project Summary: A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet clinical need of inoperable patients with severe aortic stenosis (AS). Recent longitudinal follow-up studies of TAVR patients however indicate that this procedure and associated technology may result i ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Integrated Platform for Mass-Spectrometric Studies of Protein Structure

    SBC: Protein Metrics Inc.            Topic: 400

    Summary Technology for studying the higher order structure (HOS) and interactions of biomolecules is a highlighted NIGMS SBIR/STTR research topic. Mass-spectrometric methods for studying HOS include hydroxyl radical footprinting as well as chemical methods to covalently label amino acid side-chain functional groups, and also hydrogen/deuterium exchange (HDX) on protein backbone amides. These metho ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacological chaperones for the treatment of Open-Angle Glaucoma

    SBC: Viewpoint Therapeutics, Inc.            Topic: NEI

    Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease

    SBC: PELICAN THERAPEUTICS, INC.            Topic: NIAID

    PROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government